The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone-Reference-Cited by-同舟云学术

The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone

Published:2016-09-22 Issue:8 Volume:115 Page:967-973
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Campbell Esther J,Tesson Mathias,Doogan Flora,Mohammed Zahra MA,Mallon Elizabeth,Edwards Joanne

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2016206.pdf

Reference25 articles.

1. Allred DC, Carlson RW, Berry DA, Burstein HJ, Edge SB, Goldstein LJ, Gown A, Hammond ME, Iglehart JD, Moench S, Pierce LJ, Ravdin P, Schnitt SJ, Wolff AC (2009) NCCN Task Force Report: estrogen receptor and progesterone receptor testing in breast cancer by immunohistochemistry. J Natl Compr Canc Netw 7 (Suppl 6): S1–S21;, quiz S2–S3.

2. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD (1996) Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74 (9): 1445–1451.

3. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkila P, Heikkinen T, Nevanlinna H, Akslen LA, Begin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, Garcia-Closas M, Caldas C, Pharoah PD, Huntsman D (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7 (5): e1000279.

4. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ (2015) -Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26 (8): 1533–1546.

5. Cowen PN, Teasdale J, Jackson P, Reid BJ (1990) Oestrogen receptor in breast cancer: prognostic studies using a new immunohistochemical assay. Histopathology 17 (4): 319–325.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correlating Receptor Status with Nottingham Prognostic Index in Breast Cancer;Indian Journal of Surgery;2023-07-22

2. Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer;npj Breast Cancer;2023-05-31

3. Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer;Journal of Breast Cancer;2023

4. Morphological Features and Immunohistochemical Profiling of Male Breast Gynaecomastia; A Large Tissue Microarray Study;Frontiers in Oncology;2022-06-23

5. EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS;ACTA MEDICA MEDITERR;2022